CD274 and neoplasm: While section 2.5 presented clinical evidence supporting exo-PD-L1 as a biomarker for tumor progression and immunotherapy response, this section highlights the comparative advantages of exo-PD-L1 over other circulating and tissue-based biomarkers, such as IHC-PD-L1, ctDNA, and soluble PD-L1.